Subtopic Deep Dive
Pyrrolobenzodiazepine Antibody-Drug Conjugates
Research Guide
What is Pyrrolobenzodiazepine Antibody-Drug Conjugates?
Pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) are monoclonal antibody-based therapeutics that deliver dimeric PBD DNA cross-linking payloads via engineered linkers to target tumor antigens.
PBDs form covalent aminal bonds at the C11-position with guanine C2-NH2 groups in the DNA minor groove (Mantaj et al., 2016, 250 citations). These ADCs use site-specific conjugation, such as engineered cysteines with valine-alanine dipeptide linkers, to enhance stability and efficacy (Jeffrey et al., 2013, 241 citations). Over 10 key papers since 2013 document their preclinical and clinical development, with 124 citations for ADCT-301 targeting CD25 in lymphomas (Flynn et al., 2016).
Why It Matters
PBD-ADCs enable targeted delivery of highly potent DNA cross-linkers to tumors, reducing systemic toxicity compared to free PBDs, as shown in preclinical models with superior antitumor activity (Jeffrey et al., 2013, 241 citations). Clinical trials of camidanlumab tesirine (ADCT-301) in relapsed Hodgkin lymphoma achieved durable responses via CD25 targeting (Hamadani et al., 2018, 41 citations). Fractionated dosing improved the therapeutic index in solid tumor xenografts by minimizing off-target effects (Hinrichs et al., 2017, 43 citations), supporting precision oncology applications.
Key Research Challenges
Linker Stability Optimization
Noncleavable linkers in PBD-ADCs must balance payload release in tumors without premature cleavage, as premature instability reduces efficacy (Gregson et al., 2017, 36 citations). Rational design of maleimide-based linkers addresses this but requires evaluation of conjugation efficiency. Preclinical data show variable DAR impacts pharmacokinetics (Ma et al., 2016, 27 citations).
Acquired Resistance Mechanisms
Tumors develop resistance to PBD-ADCs via ABC transporter efflux, particularly MRP1 and BCRP, reducing intracellular payload accumulation (Corbett et al., 2020, 28 citations). This limits durability in hematologic and solid tumors. Strategies to overcome transporter-mediated resistance remain underdeveloped.
Dose Fractionation Tolerability
Single high doses of PBD-ADCs cause toxicity due to persistent DNA cross-links, while fractionated regimens improve the therapeutic index without losing efficacy (Hinrichs et al., 2017, 43 citations). Optimizing schedules requires balancing bystander killing and off-target effects. Clinical translation needs further pharmacokinetic modeling.
Essential Papers
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Julia Mantaj, Paul J. Jackson, Khondaker Miraz Rahman et al. · 2016 · Angewandte Chemie International Edition · 250 citations
Abstract The pyrrolo[2,1‐c][1,4]benzodiazepines (PBDs) are a family of sequence‐selective DNA minor‐groove binding agents that form a covalent aminal bond between their C11‐position and the C2‐NH 2...
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · 2013 · Bioconjugate Chemistry · 241 citations
A highly cytotoxic DNA cross-linking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines...
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Michael Flynn, Francesca Zammarchi, Peter Tyrer et al. · 2016 · Molecular Cancer Therapeutics · 124 citations
Abstract Despite the many advances in the treatment of hematologic malignancies over the past decade, outcomes in refractory lymphomas remain poor. One potential strategy in this patient population...
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley, Michael Flynn, John P. Bingham et al. · 2018 · Scientific Reports · 122 citations
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
Mary Jane Hinrichs, Pauline M. Ryan, Bo Zheng et al. · 2017 · Clinical Cancer Research · 43 citations
Abstract Purpose: To use preclinical models to identify a dosing schedule that improves tolerability of highly potent pyrrolobenzodiazepine dimers (PBDs) antibody drug conjugates (ADCs) without com...
Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
Mehdi Hamadani, Graham P. Collins, Felipe Samaniego et al. · 2018 · Blood · 41 citations
Abstract Introduction: CD25 is expressed on the cell surface of many lymphomas, including classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma. ADCT-301 (camidanlumab tesirine [Cami-T]) is an ...
Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers
Stephen J. Gregson, Luke A. Masterson, BinQing Wei et al. · 2017 · Journal of Medicinal Chemistry · 36 citations
Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody-drug conjugates (ADCs). They lack a cleavable trigger in the linker ...
Reading Guide
Foundational Papers
Start with Jeffrey et al. (2013, 241 citations) for site-specific PBD-ADC conjugation to anti-CD70, then Mantaj et al. (2016, 250 citations) for PBD history and chemistry basics.
Recent Advances
Study Flynn et al. (2016, 124 citations) on ADCT-301 preclinical data, Hartley et al. (2018, 122 citations) on SG3199 warhead pharmacology, and Corbett et al. (2020, 28 citations) on resistance mechanisms.
Core Methods
Core techniques include C11-guanine covalent binding (Mantaj et al., 2016), engineered cysteine conjugation (Jeffrey et al., 2013), noncleavable linkers (Gregson et al., 2017), and xenograft PK modeling (Ma et al., 2016).
How PapersFlow Helps You Research Pyrrolobenzodiazepine Antibody-Drug Conjugates
Discover & Search
Research Agent uses searchPapers with query 'Pyrrolobenzodiazepine Antibody-Drug Conjugates linker stability' to retrieve 20+ papers including Jeffrey et al. (2013, 241 citations), then citationGraph maps backward citations to foundational PBD conjugation work and findSimilarPapers identifies related ADCs like ADCT-301 (Flynn et al., 2016). exaSearch uncovers niche reviews on PBD warheads like Hartley et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract linker structures from Gregson et al. (2017), then runPythonAnalysis with pandas to quantify DAR distributions from Ma et al. (2016) pharmacokinetics data, verifying bystander effects via statistical plots. verifyResponse (CoVe) with GRADE grading cross-checks claims on resistance mechanisms against Corbett et al. (2020), flagging low-evidence transporter interactions.
Synthesize & Write
Synthesis Agent detects gaps in resistance countermeasures post-2020 via gap detection on 50+ papers, then Writing Agent uses latexEditText to draft conjugation schemes, latexSyncCitations to integrate (Mantaj et al., 2016), and latexCompile for a methods section. exportMermaid generates flowcharts of PBD-DNA cross-linking mechanisms from Hartley et al. (2018).
Use Cases
"Compare pharmacokinetics of PBD-ADCs in xenograft models using Python analysis"
Research Agent → searchPapers('PBD-ADC pharmacokinetics xenograft') → Analysis Agent → readPaperContent(Ma et al. 2016) + runPythonAnalysis(pandas plot AUC/DAR ratios) → matplotlib figure of tumor vs. organ uptake.
"Draft LaTeX section on noncleavable PBD linker synthesis"
Synthesis Agent → gap detection → Writing Agent → latexEditText(structure from Gregson et al. 2017) → latexSyncCitations(10 refs) → latexCompile → PDF with schemes.
"Find GitHub repos implementing PBD-ADC simulation models"
Research Agent → paperExtractUrls(Hartley et al. 2018) → paperFindGithubRepo → githubRepoInspect → code for DNA cross-link kinetics simulation.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(250M OpenAlex) → citationGraph(PBD-ADCs) → DeepScan(7-step verify on Jeffrey et al. 2013) → structured report with GRADE scores on clinical efficacy. Theorizer generates hypotheses on ABC transporter inhibitors from Corbett et al. (2020) + Hartley et al. (2018) warhead data, chaining to runPythonAnalysis for binding affinity predictions.
Frequently Asked Questions
What defines Pyrrolobenzodiazepine Antibody-Drug Conjugates?
PBD-ADCs conjugate dimeric PBD DNA cross-linkers via stable linkers to antibodies targeting tumor antigens like CD70 or CD25 (Mantaj et al., 2016; Jeffrey et al., 2013).
What are key methods in PBD-ADC development?
Site-specific cysteine conjugation with valine-alanine linkers and noncleavable maleimide drug-linkers enable precise DAR control and payload delivery (Jeffrey et al., 2013; Gregson et al., 2017).
What are landmark papers on PBD-ADCs?
Jeffrey et al. (2013, 241 citations) introduced anti-CD70 PBD-ADCs; Mantaj et al. (2016, 250 citations) reviewed PBD evolution; Flynn et al. (2016, 124 citations) detailed ADCT-301.
What open problems exist in PBD-ADCs?
Overcoming ABC transporter resistance (Corbett et al., 2020) and optimizing fractionated dosing for solid tumors (Hinrichs et al., 2017) limit broader clinical use.
Research Synthesis and pharmacology of benzodiazepine derivatives with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pyrrolobenzodiazepine Antibody-Drug Conjugates with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers